Literature DB >> 14654947

Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.

Hiroyuki Yamasaki1, Satoshi Ikeda, Masazumi Okajima, Yoshio Miura, Toshimasa Asahara, Nobuoki Kohno, Fumio Shimamoto.   

Abstract

Alterations in the expression of mucin family members play an important role as well as alterations in oncogenes and onco-suppressor genes in carcinogenesis and progression of pancreatic cancer. We analyzed the expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen (SIMA) in pancreatic tumors. MUC1 expression was observed in almost all samples, whereas MUC2 expression was not. MUC5AC expression was observed in 73.9% of the cancerous regions, 48.7% of the dysplastic regions and 72.0% of the hyperplastic regions but not in the normal pancreatic duct. SIMA expression was observed in 45.7% of cancerous regions, 17.9% of the dysplastic regions and 8.0% of the hyperplastic regions. Furthermore, stromal expression of MUC1, MUC5AC and SIMA was observed in 37.0%, 60.9% and 26.1% of the cancerous regions, respectively. Stromal expression of these mucins was not observed in the hyperplastic regions and normal pancreatic duct and was observed in only two dysplastic regions. The survival of pancreatic cancer patients with stromal expression of MUC1 or SIMA was worse than that of other patients (P=0.04). In conclusion, the localization of mucin expression, especially stromal expression of MUC1 or SIMA, might be a prognostic factor for patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14654947

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.

Authors:  Sabrina C Sopha; Purva Gopal; Nipun B Merchant; Frank L Revetta; David V Gold; Kay Washington; Chanjuan Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 2.  Mucins in pancreatic cancer and its microenvironment.

Authors:  Sukhwinder Kaur; Sushil Kumar; Navneet Momi; Aaron R Sasson; Surinder K Batra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-16       Impact factor: 46.802

Review 3.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.

Authors:  Fuqin Su; Hongyan Li; Chaoqi Yan; Baoqing Jia; Yi Zhang; Xiaoguang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

Review 5.  Biological approaches to therapy of pancreatic cancer.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Pancreatology       Date:  2008-08-25       Impact factor: 3.996

Review 6.  Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.

Authors:  Shiv Ram Krishn; Koelina Ganguly; Sukhwinder Kaur; Surinder K Batra
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

Review 7.  Targeted therapies for pancreatic cancer.

Authors:  S A Danovi; H H Wong; N R Lemoine
Journal:  Br Med Bull       Date:  2008-08-27       Impact factor: 4.291

8.  Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer.

Authors:  Masaki Tomita; Takanori Ayabe; Eiichi Chosa; Naohiro Nose; Kunihide Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-08-11

Review 9.  What is recent in pancreatic cancer immunotherapy?

Authors:  Elena Niccolai; Domenico Prisco; Mario Milco D'Elios; Amedeo Amedei
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

Review 10.  Immunotherapy for pancreatic cancer.

Authors:  Elias Kotteas; Muhammad Wasif Saif; Konstantinos Syrigos
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-03       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.